Simple blood count may forecast deadly transplant complication
NCT ID NCT07508345
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether counting a specific type of cell in the blood (circulating endothelial cells) can predict the risk of acute graft-versus-host disease (GVHD) in adults receiving a stem cell transplant for blood cancer. Researchers measured these cells before transplant in 50 patients. The goal was to see if higher counts could identify those more likely to develop GVHD, a serious immune reaction.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple blood test to identify patients at high risk for acute GVHD before symptoms appear.
- What could go wrong
- This is a small, completed observational study, not a treatment trial. The findings may not be confirmed in larger, more diverse groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Pavia, 27100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a skin biopsy reveal how axatilimab fights scarring in chronic GVHD?
- New drug shows promise in controlling transplant complications
- Simple blood test could predict transplant complications
- Which drug better prevents transplant complications in older leukemia patients?
- New drug cocktail aims to stop transplant rejection
- Blood pressure drug tested to prevent transplant complication